Patent ID: 7740849
Filing Date: 2010-06-22
Classification: A61K,G01N

Abstract:
1. A method of treating a pregnancy related hypertensive disorder in a subject on or after the 20 th week of pregnancy, said method comprising the step of administering to said subject (i) a compound capable of decreasing soluble endoglin expression levels or soluble endoglin biological activity, wherein said compound is an antibody that specifically binds soluble endoglin, or a soluble endoglin antigen binding fragment thereof, or a growth factor that binds to soluble endoglin and (ii) a compound capable of decreasing sFlt-1 expression levels or sFlt-1 biological activity, wherein said compound is an antibody that specifically binds sFlt-1, or an sFlt-1 antigen binding fragment thereof, or a growth factor that binds to sFlt-1, wherein said administering is on or after the 20 th week of the pregnancy of said subject and wherein said administering is for a time and in an amount sufficient to treat said pregnancy related hypertensive disorder in said subject.